Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2005
11/01/2005US6960598 (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses
11/01/2005US6960597 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
11/01/2005US6960583 Pyrazolotriazines as CRF antagonists
11/01/2005US6960581 1-amino-2-hydroxy-butane or 2-hydroxy-butanamide derivatives
11/01/2005US6960578 Glutamate receptor antagonists
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
11/01/2005CA2264852C Use of methylphenidate or a pharmaceutically acceptable salt thereof
11/01/2005CA2115792C Method for the treatment of pain
10/2005
10/28/2005CA2565002A1 Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
10/27/2005WO2005100577A1 Method for gene delivery to neuronal cells
10/27/2005WO2005100563A1 Follistatin mutant polypeptide
10/27/2005WO2005100562A1 OSTEOPONTIN siRNA
10/27/2005WO2005100355A1 Cyclic amine compound
10/27/2005WO2005100351A1 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
10/27/2005WO2005100337A1 Substituted dioxolane derivatives and their use of preparing the neuroregulator
10/27/2005WO2005100325A1 Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
10/27/2005WO2005100324A1 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
10/27/2005WO2005099760A1 Solid pharmaceutical preparation
10/27/2005WO2005099741A1 Remedy for motoneuron diseases
10/27/2005WO2005099697A1 Use of phencynonate hydrochloride for treating or alleviating epilepsy
10/27/2005WO2005099696A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005WO2005099681A1 Tablet containing branched chain amino acid and process for producing the same
10/27/2005WO2005099671A2 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005WO2005040835A3 Method for determining the antiradical defense potential and use thereof, in particular in veterinary and human preventive therapeutics
10/27/2005WO2004089366A8 Bicyclic compounds as nr2b receptor antagonists
10/27/2005WO2004048330A8 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
10/27/2005WO2003023008A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/27/2005US20050239899 Beta-secretase inhibitors
10/27/2005US20050239896 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke, depression, glaucoma
10/27/2005US20050239872 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
10/27/2005US20050239863 Indole diterpene natural product and synthetic compound; Potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239851 Substituted benzoxazoles as estrogenic agents
10/27/2005US20050239849 Substituted phenoxyacetic acids
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239828 Spirocyclic amides as cannabinoid receptor modulators
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239822 Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines
10/27/2005US20050239808 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
10/27/2005US20050239802 E.g., 6-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)- phenyl]cyclopent-1-enyl}-pyridine-2-carboxylic acid, used to treat prostaglandin mediated diseases that include inflammatory, neuropathic or visceral pain
10/27/2005US20050239799 1-phenyl-4-benzylpiperazines dopamine receptor subtype
10/27/2005US20050239797 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity
10/27/2005US20050239789 2-(9-bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)-cyclobutanone; treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea
10/27/2005US20050239788 Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor
10/27/2005US20050239787 Novel maxi-k channel blockers, methods of use and process for making the same
10/27/2005US20050239786 Triazole derivatives as tachykinin receptor antagonists
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239774 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
10/27/2005US20050239773 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
10/27/2005US20050239768 Trans-(4a,9b)-2-methyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indol-6-yl-4-methylphenyl sulfide; 5-HT2 receptor modulation; schizophrenia, anxiety, depression, and migraines
10/27/2005US20050239741 use in the field of neuroprotection and cancer treatment (neuroblastoma tumors)
10/27/2005US20050239684 Compounds which inhibit beta-secretase activity and methods of use thereof
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239169 Nucleotide sequences coding seladin-1polypeptide for use in treatment and prevention of alzheimer's disease
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239069 which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells; gene therapy
10/27/2005US20050239062 diagnosing Alzheimer's disease by measuring abundance of low-density lipoprotein receptor related protein-1 (LRP-1), abundance of transcripts thereof, or LRP-1 receptor activity and comparing with an age-matched control
10/27/2005US20050238741 Composition comprising an extract of liriopsis tuber for protecting brain cells and improving memory
10/27/2005US20050238726 N-methyl D-aspartic acid (NMDA) receptor antagonism; neuroprotection
10/27/2005US20050238715 Developing a delivery system for multi-pharmaceutical active materials at various release rates
10/27/2005US20050238625 Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration
10/27/2005CA2563689A1 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005CA2563386A1 Selected cgrp-antagonists, their preparation processes and their use as medicaments
10/27/2005CA2563010A1 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
10/27/2005CA2562937A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
10/27/2005CA2562885A1 Follistatin variant polypeptide
10/27/2005CA2562694A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005CA2562529A1 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
10/27/2005CA2562526A1 Selected cgrp antagonists, method for producing the same and the use thereof as drugs
10/27/2005CA2562406A1 Cyclic amine compound
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/27/2005CA2562069A1 Therapeutic combination for treatment of alzheimers disease
10/27/2005CA2561895A1 Polycyclic pyrimidines as potassium ion channel modulators
10/27/2005CA2560346A1 Polycyclic pyridines as potassium ion channel modulators
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1589008A1 A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1588707A1 Stable solid medicinal composition for oral administration
10/26/2005EP1588705A1 Use of coumarin derivatives
10/26/2005EP1588701A2 Rapidly-decomposing dosage form for releasing nicotine in the oral cavity or in bodily cavities
10/26/2005EP1587821A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
10/26/2005EP1587801A1 A process for preparing duloxetine and intermediates for use therein
10/26/2005EP1587799A1 Benzoxazole derivatives and their use as adenosine receptor ligands
10/26/2005EP1587798A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
10/26/2005EP1587796A1 Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands
10/26/2005EP1587789A2 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
10/26/2005EP1587788A1 2,7-substituted indoles and their use as 5-ht6 modulators
10/26/2005EP1587782A1 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
10/26/2005EP1587781A1 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
10/26/2005EP1587547A2 Amyloid-binding, metal-chelating agents
10/26/2005EP1587530A2 The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
10/26/2005EP1587527A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
10/26/2005EP1587506A2 Administration of capsaicinoids
10/26/2005EP1587499A1 Nanoparticulate topiramate formulations
10/26/2005EP1440071B1 Imidazopyridine compounds as 5-ht 4? receptor modulators
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP1397354B1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
10/26/2005EP1381607B1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/26/2005EP1328236A4 Methods of decreasing or preventing pain using spicamycin derivatives
1 ... 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 ... 1833